clinical trial

[Synthetic Biologics, Inc.] Synthetic Biologics, Inc., a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases, announced that patient dosing and observation has been completed in its Phase I clinical trial of SYN-020 intestinal alkaline phosphatase.

[TRACON Pharmaceuticals, Inc.] TRACON Pharmaceuticals, Inc. announced that the FDA has granted Orphan Drug Designation to envafolimab, a novel, single-domain antibody against PD-L1, for the treatment of patients with soft tissue sarcoma following submission of an amended application that included Phase I clinical trial data from sarcoma patients treated with single agent envafolimab.

[npj Precision Oncology] In vitro and ex vivo analyses of pentraxin 3, in human PDAC samples, pancreatic stellate cells (PSCs), cell lines and transgenic mouse model for PDAC, suggested that pentraxin 3 originated from stromal cells, mainly PSCs.

[Venatorx Pharmaceuticals] Venatorx Pharmaceuticals announced that the first patient was dosed in a Phase I clinical trial evaluating VNRX-9945, a highly potent, broadly active viral replication inhibitor for the treatment of chronic hepatitis B virus infection.

[Syndax Pharmaceuticals, Inc.] Syndax Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track Designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation. SNDX-5613 is the company's highly selective, oral menin inhibitor.

[Leukemia] Investigators conducted a phase I clinical trial of H3B-8800, an oral small molecule that bound Splicing Factor 3B1 (SF3B1), in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.